medigraphic.com
ISSN 0035-0052 (Print)

2004, Number 3

<< Back Next >>

Rev Mex Pediatr 2004; 71 (3)

Utility of the treatment with nelfinavir and two inverse transcriptase inhibitors in children with HIV/AIDS

Borjas-Ale P, Alonzo-Vázquez F, Palma-Chan A

Language: Spanish
References: 30
Page: 128-132
PDF size: 59.59 Kb.


ABSTRACT

Purpose. To determine the usefulness of an HIV-AIDS in children treatment scheme using a combination of two inverse transcriptase inhibitors and nelfinavir. Method. HIV-AIDS pediatric patients, the initial management were two inverse transcriptase inhibitors and Nelfinavir. Physical checkups were made at the beginning of this study, and every 30 days during six months; laboratory checkups, at three and six months. Data were analyzed with Wilcoxon and t Test. Results. Twelve patients were included, most of them had a significally gain of weight and height. There was an important clinical and immunological improvement without several laboratory changes. Conclusion. The scheme used in this study is useful for the management of pediatric patients with HIV-AIDS. Virus count decreased, and CD4 cells increased, specially in those children without previous treatment.


REFERENCES

  1. Roger MF, Thomas PA, Starcher ET et al. Acquired immunodeficiency syndrome in Children: report of the Center for Disease Control National Surveillance, 1982-1985. Pediatrics 1997; 79: 1008-14.

  2. Center for Disease Control and Prevention. HIV-AIDS Surveillance. 1995; 7: 1-29.

  3. European Collaborative Study Group. Risk Factors for Mother to Child transmission of HIV-1. Lancet 1992; 339: 1007-12.

  4. Gabiano CP, Tovo PA, De Martiniano M et al. Mother to Child Transmission of Human immunodeficiency Virus Type 1: risk of infection and correlates of transmission. Pediatrics 1992; 90: 369-74.

  5. Raszka WV, Meyer GA Jr, Waecker NJ et al. Variability Pf Serial Absolute and Percent CD4 Lymphocyte Counts in Healthy Children Born to Human Immunodeficiency Virus-1 Infected Parents. Pediatr Infect Dis J 1994; 13: 70-72.

  6. Gibb DM, MacDonagh SE, Tookey PA et al. Uptake of Interventions to Reduce Mother to Child Transmission of HIV in the United Kingdom and Ireland. AIDS 1997; 11: F53-F58.

  7. Connor EM, Sperling RS, Golber R et al. Reduction of Maternal Infant Transmission of Human Immunodeficiency Virus Type 1 With Zidovudina Treatment. N Engl J Med 1994; 331: 173-1180.

  8. Domachowske JB. Pediatric Human Immunodeficiency Virus Infection. Clin Microbiol Rev 1996; 9: 448-68.

  9. Center for Disease Control and Prevention. Recommendations of The U.S. Public Health Service Task Force on the Use of Zidovudina to Reduce Perinatal Transmission of Human Immunodeficiency Virus. MMWR 1994; 43 (No. RR-11).

  10. Center for Disease Control and Prevention. Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected With HIV-1. For Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States. MMWR 1998; 47 (No. RR-2).

  11. Working Group on Antiretroviral Therapy, National Pediatric HIV Resource Center. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. MMWR 2001: 1-70.

  12. Perelson AS, Newmann AU, MacKuwitz M, Leonard JM, Ho DD. HIV-1 Dynamics In Vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 1582-86.

  13. Havlir DV, Richman DD. Viral Dynamics of HIV Implications for Drug Development and Therapeutic Strategies. Ann Intern Med 1996; 271: 1582-86.

  14. Mellors JW, Kingsley LA, Rinaldo CR et al. Quantification of HIV-1 RNA in Plasma Predicts Outcome After Seroconversion. Ann Intern Med 1995; 122: 573-79.

  15. Delaware C, Bungard M, Mayaux MJ et al. HIV-1 RNA Detection in Plasma for the Diagnostic of Infection in Neonates. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1997; 15: 121-25.

  16. Stein DS, Lyles RH, Neil MH et al. Predicting Clinical Progression of Death in Subjects With Early-Stage Human Immunodeficiency Virus Infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and B2- microglobulin. J Infect Dis 1997; 176: 1161-67.

  17. Katzenstein TL, Pedersen C, Nielson C et al. Longitudinal Serum HIV-RNA Quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS 1996; 10: 167-73.

  18. Butler KM, Husson RN, Balis M et al. Dediexyinosine in Children with Symptomatic Human Immunodeficiency Virus Infection. N Engl J Med 1991; 324: 137-44.

  19. Lewis LL, Venzon D, Church LA et al. Lamivudine in Children with Human Immunodeficiency Virus Infection: a phase I/II study. J Infec Dis 1996; 174: 16-25.

  20. Kline MW, Dukle LM, Church JA et al. A Phase I/II Stavudine (d4T) in Children with Human Immunodeficiency Virus Infection. Pediatrics 1995; 96: 247-52.

  21. Kline MW, Van Dyke RB, Lindsey JC et al. A Randomized Comparative Trial of Stavudine (d4T) versus Zidovudine (ZDV, AZT) in Children with Human Immunodeficiency Virus Infection. Pediatrics 1998; 101: 214-20.

  22. Center for Disease Control and Prevention. Guidelines for the use of Antiretroviral Agents in Pediatric HIV Infection. MMWR 1998; 47 (No. RR-4): 1-45.

  23. Rutstein RM, Feingold A, Meislich D, Word B, Rudy B. Protease Inhibidor Therapy in Children with Perinatally Acquired HIV Infection. AIDS 1997; 11: F107-F11.

  24. Luzuriaga K, Bryson I, Krogstad P et al. Combination Treatment With Zidovudine, Didanosine, and Nevirapine in Infants With Human Immunodeficiency Virus Type 1 Infection. N Engl J Med 1997; 336: 1343-9.

  25. Funk MB, Linde R, Wintergerst U et al. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS (England), 1999; 13: 1653-8.

  26. Starr SE, Fletcher CV, Spector SA et al. Combination therapy with efavirenz, nelfinavir and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type I. Pediatric AIDS Clinical Trials Group 382 Team. N Eng J Med 1999; 341: 1874-81.

  27. Pai VB, Nahata MC. Nelfinavir mesylate: a protease inhibitor. Ann Pharmacother (United States) 1999; 33: 325-39.

  28. Jarvis B, Faulds D. Nelfinavir. A review of this therapeutic efficacy in HIV infection. Drugs (New Zealand) 1998; 56: 147-67.

  29. Project Inform. Information, inspiration and advocacy for people living with HIV/AIDS. 2000: 1-6.

  30. Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs (New Zealand) 2000; 59: 581-620.




2020     |     www.medigraphic.com